In this DCVax-L trial, 223 patients were ≥30 months past their surgery date as of this analysis; 30.0% have lived ≥30 months and these patients have Kaplan-Meier (KM) -derived median survival estimate of 46.5 months.
Also as of this analysis, 182 patients were ≥36 months past their surgery date; 24.2% have lived ≥36 months and these patients have KM-derived median survival estimate of 88.2 months.
The top 100 patients of the total 331 patients in the trial showed particularly extended survival, with median survival of 40.5 months from surgery. This extended survival was not fully explained by known prognostic factors.
Northwest Biotherapeutics is focused on developing personalized immunotherapy products designed to treat cancers both more effectively and more cost-effectively than current treatments, without toxicities of the kind associated with chemotherapies, in both North America and Europe. The company has a broad platform technology for DCVax dendritic cell-based vaccines.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma